About
About Wuhan Easy Diagnosis Biomedicine Co.,Ltd
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services, as well as nutrition and health products for immune, gut, reproductive, and sleep health management. It also provides information software and supporting hardware products. In addition, the company offers blood gas and chemistry analyzers, fluorescence immunoassay analyzers, molecular diagnosis kit, coagulation analysis machine, and automated glycohemoglobin detection machine. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Visit company website
5 years, 5 months ago
Wuhan Easy Diagnosis Biomedicine Co.,Ltd is currently in a long term uptrend where the price is trading 15.7% above its 200 day moving average.
From a valuation standpoint, the stock is 30.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd's total revenue rose by 637.9% to $280M since the same quarter in the previous year.
Its net income has increased by 3353.4% to $156M since the same quarter in the previous year.
Finally, its free cash flow grew by 279.5% to $30M since the same quarter in the previous year.
Based on the above factors, Wuhan Easy Diagnosis Biomedicine Co.,Ltd gets an overall score of 5/5.